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In recent years, an increasing pressure has been put on researchers to provide 
not only scientific impact, but also social or economic impact of their scientific findings.1 
Given the different nature of science, it is not equally straightforward to have a clear 
sight of the beneficial outcome of scientific research for society. Whereas in applied 
research one focuses on pragmatic questions and aspires to develop applications that 
can be implemented directly in current practice, in basic research emphasis lies more in 
expanding and exploring the underlying mechanism(s) of processes of interest without 
primarily aiming to develop specific applications. However, these two types of research 
should ideally complement each other in order to span the entire trajectory from bedside 
to bench and vice versa.2 
Platelets have an essential role in hemostatic system.  Upon vascular damage, 
platelets are in the frontline and rapidly form a platelet plug in order to cessate bleeding. 
However, aberrant platelet function can cause imbalance of the hemostatic process, 
potentially leading to thrombosis or bleeding, and hence cardiovascular events.3 
Commonly, anti-platelet drugs are chosen to prevent cardiovascular events of the 
arteries, in conjunction with lipid-lowering medication and anti-hypertensive agents. 
Bleeding is the main negative side effect of anti-platelet drugs. Unfortunately, current 
platelet function tests in general lack sensitivity for predicting bleeding or thrombosis 
risks. Studies evaluating methods for monitoring platelet function upon anti-platelet 
treatment revealed that results from light transmission aggregometry (LTA), PFA-100, 
VerifyNow do not correlate well.4,5 Furthermore, clinical studies have also shown that the 
correction of anti-platelet treatment based on results from platelet function analysis did 
not improve the clinical outcome in patients.6 So far, it is unknown whether monitoring 
is actually useful for clinical practice.
In my thesis, I focused on unraveling the consequences of the effect of changes 
in platelet function, either due to genetic deficiency or pharmacological modulation, on 
platelet function and thrombus formation. Throughout the thesis, an in vitro microfluidic 
device was employed to study platelet function under shear conditions. The capability 
of this test to monitor platelet function has been shown before,7 however it has not 
been extensively used with patient blood.  In Chapter 4, this microfluidic device has been 
employed to characterize platelet function in platelets from immunodeficient patients. 
For the first time, we could confirm that the genetic alteration causing immunodeficiency 
affected platelet function, which could explain the increased bleeding risk. Improvement 
of platelet function could also be recognized by this method as in samples from the same 
patients after bone marrow transplantation an improved platelet function was detected
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Besides studying the effect of genetic alterations on platelet thrombus formation, 
this microfluidic device can be also used for testing the effect of pharmacological agents, 
such as drug candidates with direct effect on platelets or with regards to monitoring the 
indirect effect of other medication on platelet function, as is described in Chapter 7 and 
9. Chapter 9 aimed to explain the reduction in cardiovascular events upon Dipeptidyl 
peptidase-4 antagonist treatment by linagliptin and sitagliptin. By using this microfluidic 
device, we unraveled a negative priming effect on platelets as an indirect effect of this 
treatment. The latter illustrates the diverse range of applicability of in vitro microfluidic 
devices. 
Furthermore, microfluidic devices are ideal to investigate the interplay between 
platelets and other cell types, for instance endothelial cells8 or immune cells. In Chapter 
5, the interaction between platelets and leukocytes have been extensively studied 
thereby focusing on the consequences of platelet inhibition on leukocyte activation and 
responses. Here, the inhibition of platelet secretion is appeared to reduce the leukocyte 
activation in vitro. Given the increasing interest in thrombo-inflammation, it is important 
aspect to be able to monitor such interactions between platelets and inflammatory/
inflamed cells. 
A recent paper highlighted that in vitro thrombus formation measurements 
are good reflection of results obtained in experimental mouse models for collagen-
dependent arterial thrombosis,9 supporting the relevance of such an in vitro device and 
suggesting their possible involvement into the 3R approaches by reducing, refining and 
replacing animal experiments. In Chapter 6, we have compared the in vitro thrombus 
formation results assayed with blood from 33 different genetically modified mouse 
strains using a standardized image analysis protocol. The original microfluid experiments 
were performed over the last decade using the same protocol and device but in different 
laboratories. These comparisons unraveled that despite of the difference in time, the 
results are comparable. This is an important finding for future application and for 
developing a possible point-of-care device. 
In this thesis, only one type of microfluidic device has been employed, but there are 
many commercial and costume-made microfluidic devices available for studying platelet 
functions under physiological and pathological conditions.10 Currently, no uniform 
guidelines exist on how to employ microfluidic devices and how to report the obtained 
results. In theory, laboratories using the same devices, could perform the experiment 
differently, thereby hampering comparison of results. To overcome this problem, the 
Biorheology Subcommittee of the Scientific and Standardization Committee of the 
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ISTH initiated a multi-center study on flow assay protocols and designs in which the 
results of one common microfluidic device and one custom microfluidic device will be 
compared across several centers/laboratories. One of the goals of this multicenter study 
is to formulate a general guideline regarding the most crucial aspects of performing 
microfluidic experiments.11 As already been demonstrated in Chapter 6, using the same 
protocol and device can provide highly comparable results regardless of the executor.
Given the broad applicability of the microfluidic devices, its usage as a point-of-
care (POC) test to assess platelet function has been postulated for already a number 
of years and several devices have been tested.12 For instance, the total thrombus 
formation analysis system (T-TAS) has appeared to be suitable for recognizing the effect 
of antiplatelet and anticoagulant treatment in patients with coronary artery disease, 
acute coronary syndrome or ischemic stroke.12 However, there are issues that have to be 
solved regarding preanalytical variables and on how to perform the test in a standardized 
manner, but also on how to interpret the outcome of the test.13 At present no uniform 
cut off values have been set for microfluidic assays with regard to platelet function. Given 
the natural variability in platelet function within the normal population, cut off values 
have to be set carefully. In addition, in order to improve and understand the results from 
patients with different disease states.13
Taken together, the results obtained from different patients, healthy volunteers 
and mice give a good overview of the usefulness of microfluidic devices in unravelling 
defective platelet function. Depending on the construction, it is possible to monitor both 
loss- and gain-of-function of the platelets leading to hemorrhage or thrombosis as it was 
proven for the Maastricht flow chamber in Chapter 6. 
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